# Activity of TroVax® Alone vs. TroVax® Plus GM-CSF in Patients With Prostate Cancer

> **NCT00448409** · PHASE2 · COMPLETED · sponsor: **The Methodist Hospital Research Institute** · enrollment: 27 (actual)

## Conditions studied

- Prostatic Neoplasms

## Interventions

- **BIOLOGICAL:** TroVax
- **DRUG:** GM-CSF

## Key facts

- **NCT ID:** NCT00448409
- **Lead sponsor:** The Methodist Hospital Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-05
- **Primary completion:** 2007-04
- **Final completion:** 2007-05
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2016-03-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00448409

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00448409, "Activity of TroVax® Alone vs. TroVax® Plus GM-CSF in Patients With Prostate Cancer". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT00448409. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*